NascaCell announces an aptamer distribution agreement in Japan with GE Healthcare

25-Oct-2004

NascaCell IP GmbH announced today that it has entered into a collaboration agreement with GE Healthcare to market aptamers for target validation and drug discovery in Japan. The agreement is part of NascaCell's business strategy to make aptamers available to the life science industry.

Under the agreement, NascaCell grants GE Healthcare the exclusive rights to distribute its aptamers in Japan for target validation and drug discovery applications. GE Healthcare will initiate and negotiate agreements with prospective customers for aptamers and related services.

"We are delighted to work together with GE Healthcare to grow the market for aptamers. Because of its excellent recognition and network, GE Healthcare is our first choice as a partner," said Andreas Jenne, Ph.D., NascaCell's co-founder and chief executive officer.

Aptamers are synthetic drug-like molecules that can specifically knock-down protein functions in cells and organisms. Their rapid production and convenient handling mean aptamers can be used in numerous drug discovery applications, such as animal studies or high throughput drug screening (HTS).

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...